

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE
Curriculum Vitae

Date: 12/10/2020

Vincent Lo Re III, M.D., M.S.C.E.

Address: Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104 USA

If you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have:
none (U.S. citizen)

Education:

1992	B.S.	Georgetown University (Chemistry)
1997	M.D.	University of Pennsylvania (Medicine)
2005	M.S.C.E.	University of Pennsylvania (Pharmacoepidemiology)

Postgraduate Training and Fellowship Appointments:

1997-1998	Intern in Medicine, Hospital of the University of Pennsylvania
1998-2000	Resident in Medicine, Hospital of the University of Pennsylvania
2000-2001	Chief Medical Resident, Hospital of the University of Pennsylvania
2001-2003	Fellow in Infectious Diseases, Hospital of the University of Pennsylvania
2003-2007	Research Fellow in Pharmacoepidemiology and Infectious Diseases Epidemiology, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania

Military Service:

[none]

Faculty Appointments:

2007-2008	Instructor in Medicine and Epidemiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2008-2017	Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2008-2017	Assistant Professor of Medicine, University of Pennsylvania School of Medicine
2017-present	Associate Professor of Medicine, University of Pennsylvania School of Medicine
2017-present	Associate Professor of Epidemiology in Biostatistics and

Epidemiology, University of Pennsylvania School of Medicine
(Secondary)

Hospital and/or Administrative Appointments:

2003-present	Attending Physician, Infectious Diseases Section, Medicine Service, Philadelphia Veterans Affairs Medical Center
2004-present	Attending Physician, Infectious Diseases Division, Penn Presbyterian Medical Center
2010-present	Attending Physician, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
2015-present	Associate Director, NIGMS-funded T32 Pharmacoepidemiology Training Grant, Perelman School of Medicine

Other Appointments:

2005-2008	Faculty-Fellow, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2008-present	Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2008-present	Member, Epidemiology and Biostatistics Graduate Group, Perelman School of Medicine, University of Pennsylvania
2014-2017	Co-Director HIV/Viral Hepatitis Coinfection Scientific Working Group, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania
2017-present	Co-Director, Clinical Core, Penn Center for AIDS Research, Perelman School of Medicine, University of Pennsylvania
2018-present	Co-Director, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2020-present	Member, Penn Center for Musculoskeletal Disorders

Specialty Certification:

2000	Internal Medicine
2003	Infectious Diseases
2005	Epidemiology

Licensure:

2000-present	Pennsylvania (MD-070718-L)
--------------	----------------------------

Awards, Honors and Membership in Honorary Societies:

1992	Chemistry Achievement Award, Georgetown University
1992	Phi Beta Kappa, Georgetown University
1993	Penn Geriatrics Scholarship, Edinburgh University,

	Edinburgh, Scotland
1999	Maurice F. Attie Junior Medical Resident Teaching Award
1999	Pfizer Resident Award for Outstanding Performance in Infectious Diseases
2000	Maurice F. Attie Senior Medical Resident Teaching Award
2001	Francis H. Sterling Award for Educational Excellence
2001	"Penn Pearls" Medical Student Teaching Award
2002	Robert Austrian Fellowship Award in Infectious Diseases
2005	Young Investigator Award, 13th Conference on Retroviruses and Opportunistic Infections
2005	George McCracken Infectious Disease Fellow Travel Grant, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
2006	George McCracken Infectious Disease Fellow Travel Grant, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
2006	Young Investigator Award, 14th Conference on Retroviruses and Opportunistic Infections
2007	Top 30% Reviewer, Annals of Internal Medicine
2008	Top 10% Reviewer, Annals of Internal Medicine
2008	Top 5% Reviewer, Clinical Infectious Diseases
2009	Top 10% Reviewer, Annals of Internal Medicine
2010	Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics
2010	Clinical Infectious Diseases Award for Outstanding Reviews
2011	Penn Department of Medicine Robert Austrian Award in Health Evaluation Research
2011	Poster of Distinction Award, Digestive Disease Week
2013	Fellow, International Society for Pharmacoepidemiology
2013	Leonard Berwick Memorial Teaching Award, Penn Medicine Award of Excellence, Perelman School of Medicine
2014	Top 10% Reviewer, Annals of Internal Medicine
2014	Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics
2016	2016 HIV Medicine Association Research Award, Infectious Diseases Society of America
2020	Clinical Practices of the University of Pennsylvania Sustainable Award, "A Sustained and Enhanced Initiative for HIV Treatment and HIV/HCV Coinfection Eradication Program in the MacGregor Infectious Diseases Practice"

Memberships in Professional and Scientific Societies and Other Professional Activities:

International:

2005-present	International AIDS Society (Member)
2006-present	International Society for Pharmacoepidemiology (Member, 2006-Present;

Membership Committee Member, 2009-Present; Membership Committee Vice-Chair, 2011-2013; Membership Committee Chair, 2013-2014; Education Committee Member, 2010-Present; Academic Council Member, 2013-Present; Fellow, 2013-Present; Strategic Planning Committee Member, 2015-2018; Board of Directors, 2015-2018; Re-Branding Committee 2018-2019; President-Elect, 2020-2021; President, 2021-2022.)

2011 Health Research Board of Ireland: Clinical and Applied Biomedical Research, Infectious Diseases Study Section, Dublin, Ireland (Member)

2014-present International Conference on Pharmacoepidemiology & Therapeutic Risk Management Scientific Program Committee (Member, 2014-Present; Newcomer Track Director, 2014-2017; Scientific Program Chair, 2019)

National:

2000-present American College of Physicians (Member)

2001-present Infectious Diseases Society of America (IDSA) (Member, 2001-Present; Fellow, 2015-Present; Research Committee Member, 2015-2018)

2004-present American Association for the Study of Liver Diseases (Member)

2005-present American College of Epidemiology (Member)

2005-present HIV Medicine Association (Member)

2005-present Society for Epidemiologic Research (Member)

2007-present Veterans Aging Cohort Study (VACS) (Member 2007-Present; Liver Core Member 2007-Present; Co-Chair Liver Core 2009-Present; Executive Committee Member 2010-Present; Publications Committee 2017-Present)

2010-present North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (Member Liver Disease Working Group, HIV/HBV Coinfection Lead 2014-present)

2011-2013 FDA Mini-Sentinel Severe Liver Injury Validation Workgroup (Workgroup Leader, 2011-2013)

2013 National Institutes of Health (Study Section Member, Special Emphasis Panel/Scientific Review Group ZAI1-SM-M-C1 Study Section)

2013-2015 US Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee (Member)

2014-present American Conference for the Treatment of HIV (Member Program Committee;

Co-Chair HIV/Viral Hepatitis Program)

2015-2017	National Academies of Sciences, Engineering, and Medicine Committee for a National Strategy for the Elimination of Hepatitis B and C (Member)
2015-2018	US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (Member)
2015	US Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee (Ad Hoc Member, 2015)
2015	VA Healthcare Network Competitive Pilot Project Fund (Study Section Member)
2016	AIDS Clinical Trials Group (ACTG) Hepatitis External Advisory Committee (Member)
2017-present	American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C Guidance Panel (Member)
2017-2020	FDA Sentinel Serious Infection Validation Workgroup (Workgroup Leader, 2017-2020)
2017	National Institutes of Health (Study Section Member, Special Emphasis Panel/Scientific Review Group ZRG1 AARR-E (83) S, "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection")
2017	US Food and Drug Administration (FDA) Drug Safety and Risk Management Advisory Committee (Ad Hoc Member, 2017)
2018-present	AIDS Clinical Trials Group Hepatitis Transformative Science Group (Member)
2019	National Institutes of Health (Study Section Member, AIDS Research Review Committee)
2020-present	National Psoriasis Foundation COVID-19 Taskforce (Member)

Editorial Positions:

2002-2004	Editor, Infectious Diseases Hot Topics, Philadelphia: Hanley & Belfus, 2004
2002-2004	Editorial Advisory Board Member, JAMA, "On Call-Issues in Graduate Medical Education" Section
2005-present	Peer Reviewer, Pharmacoepidemiology and Drug Safety
2005-present	Peer Reviewer, Clinical Infectious Diseases
2005-present	Peer Reviewer, Annals of Internal Medicine
2006-present	Peer Reviewer, Alcoholism: Clinical and Experimental Research

2007-present	Peer Reviewer, International Journal of Infectious Diseases
2007-present	Peer Reviewer, Gastroenterology
2007-present	Peer Reviewer, Clinical Microbiology Reviews
2008-present	Peer Reviewer, HIV Clinical Trials
2009-present	Peer Reviewer, Liver International
2009-2017	Associate Editor, Pharmacoepidemiology and Drug Safety
2009-present	Peer Reviewer, BMC Infectious Diseases
2009-present	Peer Reviewer, JAIDS
2010-2013	Associate Editor, BMC Infectious Diseases
2010-present	Peer Reviewer, HIV Medicine
2010-present	Peer Reviewer, BMC Gastroenterology
2010-present	Peer Reviewer, European Journal of Gastroenterology and Hepatology
2011-present	Peer Reviewer, British Journal of Clinical Pharmacology
2011-present	Peer Reviewer, Hepatology
2011-present	Peer Reviewer, Journal of Hepatology
2011-present	Peer Reviewer, Journal of Medical Virology
2012-present	Peer Reviewer, AIDS and Behavior
2013-present	Peer Reviewer, AIDS
2013-present	Peer Reviewer, Antiviral Therapy
2014-present	Peer Reviewer, Journal of Antimicrobial Chemotherapy
2014-present	Peer Reviewer, New England Journal of Medicine
2015-present	Peer Reviewer, The Lancet
2016-present	Peer Reviewer, Drug Safety
2017-present	Peer Reviewer, Proceedings of the National Academy of Sciences
2018-present	Regional Editor for the Americas, Pharmacoepidemiology and Drug Safety

Academic and Institutional Committees:

2000-2001	Chair, House Staff Committee, Hospital of the University of Pennsylvania
2000-2001	Member, Graduate Medical Education Committee, Hospital of the University of Pennsylvania
2006-2013	Member, Intern Selection Committee, Hospital of the University of Pennsylvania
2007-2009	Member, Fellowship Selection Committee, Division of Infectious Diseases, Department of Medicine Perelman School of Medicine, University of Pennsylvania
2008-present	Member, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2009-present	Member, Steering Committee, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
2011-present	Chair, Service Center Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania

2011-present	Member, Special Programs in Education Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2012-present	Member, Curriculum Committee, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
2013	Member, Medical Student Research Paper Prize Committee, Perelman School of Medicine, University of Pennsylvania
2013-2016	Chair, Data Safety Monitoring Board, "A Placebo controlled trial of varenicline for smoking among those with HIV/AIDS" (R01 DA033681; PI, Robert A. Schnoll, PhD), Perelman School of Medicine, University of Pennsylvania
2014-present	Member, Infectious Diseases Research Group, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2014-present	Member, Gastroenterology and Hepatology Clinical Research Program, Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, Department of Medicine, University of Pennsylvania
2015	Search Committee Member, Academic Clinician and Epidemiologist, Good Shepherd Penn Partners, Perelman School of Medicine, University of Pennsylvania
2017-present	Vice Chair, Reputation/Visibility Committee, Penn Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2017-present	Member, Research Advisory Committee, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2018-2019	Search Committee Chair, Division of Gastroenterology Tenure Track Physician-Scientist, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
2018-present	Co-Director, Master of Science in Clinical Epidemiology Degree Program, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania
2018-present	Committee on Appointments and Promotions, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

Major Academic and Clinical Teaching Responsibilities:

2005-2013	Lecturer, "Overview of Viral Hepatitis," Frontiers in Medicine Course for Fourth-Year Penn Medical Students
2006-2013	Course Co-Director, Clinical Investigator Toolbox elective rotation for 2nd and 3rd year Medical Residents, Hospital of the University of Pennsylvania
2006-present	Lecturer, "Challenges in Conducting Epidemiologic Studies of HIV/Viral Hepatitis Coinfection," Epidemiological Methods in Infectious Diseases EPID 656

2007-present	Attending Physician, Penn Center for Viral Hepatitis, Penn Presbyterian Medical Center, 1 session/week
2007-present	Attending Physician, Infectious Diseases Consultation Service, Penn Presbyterian Medical Center, 4 weeks/year
2008-2009	Faculty Mentor and Research Advisor, Jennifer Lin, MD, Penn Medical Resident
2008-2010	Faculty Mentor and Research Advisor, Michelle DallaPiazza, MD, Penn Medical Resident
2008-2010	Faculty Mentor and Research Advisor, Omowunme Aibana, MD, Penn Medical Student Penn Scholarly Pursuit Research; Brigham and Women's Hospital Medical Resident
2008-2009	Junior Faculty Mentor and Research Advisor, Adeel A. Butt, MD, MSc, Assistant Professor of Medicine Infectious Diseases, University of Pittsburgh Medical Center
2008-2013	Infectious Diseases Fellows Educational Lecture Series, "Management of Chronic HCV Infection in HIV"
2008-2015	Faculty Mentor and Research Advisor, Alexis Ogdie-Beatty, MD, Penn Medical Resident; Penn Rheumatology Fellow; Assistant Professor of Medicine Rheumatology and Epidemiology, Perelman School of Medicine
2008-2011	Faculty Mentor and Research Advisor, Carrie L. Kovarik, MD, Assistant Professor of Dermatology, Perelman School of Medicine
2009-2018	Course Director and Instructor, Biostatistics for Epidemiologic Methods Laboratory EPID 526-527, 24 weeks, 1.5 hour lectures per week
2009-2012	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Jeffrey S. Hafkin, MD, MSCE, Infectious Diseases Fellow, 1 hour per week for 36 months, 144 contact hours, resulted in abstract at CROI and Journal publication
2009-2010	Faculty Mentor and Research Advisor, Jessica Volk, MD 4th year Penn Medical Student, 3 hours per week for 10 months, 120 contact hours resulted in Penn FOCUS Grant; 2 abstracts presented at 2011 CROI conference; Co-Author Journal publication
2009-2010	Faculty Mentor and Research Advisor, Valerianna K. Amorosa, MD Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine
2009-2012	Faculty Mentor and Research Advisor, Zachariah Dorey-Stein, Temple University Medical Student
2010-2013	Lecturer, "Effect of HCV on Bone Density and Fractures," Frontiers in Medicine Course for Fourth-Year Penn Medical Students
2010-2015	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Hillary Hernandez-Trujillo, MD, MSCE; CHOP Immunology Fellow
2010-2011	Faculty Mentor and Research Advisor, Ingi Lee, MD, MSCE, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine, resulted in 2010 Penn Center for Education and

	Research on Therapeutics Pilot Grant, Oral Abstract Presentation in 2011 American Transplant Congress, and Journal Publication
2010-present	Faculty Mentor and Research Advisor, Kimberly A. Forde, MD, PhD, MHS, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology
2010	Presenter, "Complications of HIV/HCV Coinfection: Effect of HCV on Bone Density and Fractures," Penn Center for Viral Hepatitis Research Symposium
2010-2011	Faculty Mentor and Research Advisor, Vijay Garla, PhD, Yale University Bioinformatics PhD Student
2011-present	Lecturer, "Challenges in Conducting Cohort Studies to Examine the Epidemiology of Hepatitis C Virus Infection," GI Epidemiology (EPID 658)
2011-2015	Faculty Mentor and Research Advisor, David S. Goldberg, MD, MSCE, Penn Gastroenterology Fellow; Assistant Professor of Medicine Gastroenterology and Epidemiology
2011-2015	Co-Investigator on F31 Application, Lesley S. Park, PhD, Yale University PhD in Epidemiology Student
2012-2016	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Dana D. Byrne, MD, MSCE; Penn Infectious Diseases Fellow
2012	Presenter, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients," Penn Center for Viral Hepatitis Research Symposium
2012-2014	Faculty Mentor and Research Advisor, Joseph K. Lim, MD, Assistant Professor of Medicine Gastroenterology, Yale School of Medicine
2012-2016	Master of Science in Clinical Epidemiology Thesis Committee Member, Beth N. Floyd, MD, MSCE; Penn Gastroenterology Fellow
2013-2016	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Charitha Gowda, MD, MPH, MSCE; Penn Infectious Diseases Fellow; Awarded F32 from NIAID (2015); Awarded CROI Young Investigator Award and Penn Infectious Diseases Division Robert Austrian Research Award, both in 2016, in recognition of Master's thesis research accomplishments. Thesis featured in special topical collection on HIV and Hepatitis C Coinfection collated for the 9th International AIDS Society Conference on HIV Science 2017.
2013-2014	Faculty Mentor and Research Advisor, Baligh Yehia, MD, MPP, MSHP, Assistant Professor of Medicine Infectious Diseases, Perelman School of Medicine
2013	Viral Hepatitis Grand Rounds, "Bone Disease with Hepatitis C Virus Infection and HIV/Hepatitis C Coinfection"
2013	Infectious Diseases Grand Rounds, "Hepatic Decompensation in ART-Treated HIV/HCV-Coinfected Compared to HCV-Monoinfected Patients"

2013-present	Lecture to Penn Medical Residents, "Management of Chronic HCV in HIV"
2014-2017	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Tatyana Kushner, MD, MSCE; Penn Gastroenterology Fellow; Awarded 2017 NIH Loan Repayment Program, Frank Brooks Research Award by Penn Gastroenterology Division, and 48th Annual Komarov Prize for GI Research in recognition of Master's thesis research accomplishments. 2018 AASLD Clinical, Translational and Outcomes Research Award in Liver Diseases for postdoctoral research.
2014	Viral Hepatitis Grand Rounds, "HIV/Hepatitis C Virus Coinfection: Interactive Cases"
2014	Presenter, "Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women," Penn Center for AIDS Annual Research Retreat
2014-2016	Faculty Mentor and Research Advisor, M. Elle Saine, MA, Penn Pre-Health Post-Baccalaureate Program Student, Penn Medical Student
2014-2017	Faculty Mentor and Doctoral Thesis Committee Member, Bret Zeldow, Penn PhD in Biostatistics Student, weekly meetings
2014	Infectious Diseases Grand Rounds, "Predicting Risk of End-Stage Liver Disease in HIV/HCV Patients: Can We Forecast Liver Complications?"
2014	Infectious Diseases Grand Rounds, "Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women"
2015-present	Lecturer, "Use of Automated Databases for Comparative Effectiveness Research," Methods in Patient-Centered Outcomes and Effectiveness Research EPID 624
2015	Viral Hepatitis Grand Rounds, "Epidemiology and Treatment of HIV/HCV Coinfection: 2015 Update"
2015	Infectious Diseases Grand Rounds, "Drug-Induced Acute Liver Failure"
2016	Center for Clinical Epidemiology and Biostatistics Weekly Seminar, "Pharmacoepidemiology of Drug-Induced Acute Liver Failure"
2016	Division of General Internal Medicine Grand Rounds, "Epidemiology of HIV/Viral Hepatitis Coinfection"
2016-2018	Master of Science in Clinical Epidemiology Thesis Committee Member, Dagan E. Coppock, MD; Penn Infectious Diseases Fellow
2016-2018	Course Director, Biostatistics for Epidemiologic Methods Lectures EPID 526-527, 24 weeks, 3.0 hour lectures per week
2016-2017	Faculty Mentor and Research Advisor, Mona Gizaw, Penn Undergraduate Student, Penn Access Summer Scholars Program
2016-present	Faculty Mentor and Research Advisor, Jessie Torgersen, MD, MSCE; Penn Infectious Diseases Fellow and Instructor; Highlighted Poster Presentation at 16th International Conference in Malignancies

	in HIV/AIDS (2017); CROI Young Investigator Award (2017); Oral abstract presentation at CROI 2019.
2016-2017	Faculty Mentor and Research Advisor, Kirsten Lum, PhD, Penn Department of Biostatistics, Epidemiology, and Informatics Postdoctoral Research Fellow
2017	Division of Gastroenterology Interdisciplinary Grand Rounds, "Hepatitis B Reactivation"
2017-2019	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Joanna M. Rhodes, MD, MSCE; Penn Hematology and Oncology Fellow. Awarded 2019 American Society for Clinical Oncology Conquer Cancer Foundation Young Investigator Award.
2017-present	Doctoral Thesis Committee Member, Wei (Vivian) Wang, University of Florida PhD in Pharmacoepidemiology Student
2017-present	Faculty Mentor and Doctoral Thesis Committee Member, M. Elle Saine, PhD, Penn MD/PhD in Epidemiology Student, weekly meetings. Awarded Penn Leonard Davis Institute 2018 Pilot Grant; Awarded Clinical Epidemiology Research Paper Prize for PhD dissertation by Perelman School of Medicine of the University of Pennsylvania.
2018-present	Faculty Mentor and Research Advisor, Nicole Ferrante, MD, Penn Medical Resident
2019-present	Faculty Advisor and Master of Science in Clinical Epidemiology Thesis Committee Chair, Erica Weinstein, MD; Penn Infectious Diseases Fellow
2019-present	Lecturer, "Hepatitis C Infection: Diagnosis and Treatment 2019" Penn Infectious Diseases Update 2019 for Primary Care CME conference, Philadelphia, PA
2019-present	Faculty Mentor and Research Advisor, Jessica Kim, Drexel University Medical Student
2020	Pennsylvania Hospital Department of Medicine Grand Rounds, "Management of Hepatitis C Virus Infection: Approach to Diagnosis and Initial Therapy in 2020"

Lectures by Invitation (Last 5 years):

May, 2015	"HIV/Hepatitis C Virus Epidemiology: 2015 Update" American Conference for the Treatment of HIV 2015, Dallas, TX
Jun, 2015	"Drug-Induced Acute Liver Failure in an Integrated Health System" Works in Progress Conference, VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT
Aug, 2015	"Risk of Acute Liver Failure in Patients with Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model" 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA
Aug, 2015	"Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 31st International Conference on

- Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA
- Nov, 2015 "Incidence and Determinants of Denial of Direct-Acting Antiviral Treatment for Chronic HCV Infection by Insurance Type During the First 6 Months of the Modern HCV Treatment Era" The Liver Meeting 2015, San Francisco, CA
- Mar, 2016 "Best Practices for Case Identification in U.S. Automated Claims Databases" International Society for Pharmacoepidemiology Webinar
- Apr, 2016 "HIV/Hepatitis C Virus Coinfection Management" American Conference for the Treatment of HIV 2016, Dallas, TX
- Jun, 2016 "Eliminating the Problem of Hepatitis B and C in the United States" Centers for Disease Control and Prevention/Health Resources and Services Administration Advisory Committee Meeting on HIV, Viral Hepatitis and STD Prevention and Treatment, Atlanta, GA
- Aug, 2016 "Final results of a large multi-national postmarketing safety study evaluating use of the oral anti-diabetic drug saxagliptin and risk of five outcomes" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Aug, 2016 "Risk of hepatic decompensation with cumulative mitochondrial toxic nucleoside analogue use in HIV/hepatitis C coinfection" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Aug, 2016 "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland
- Nov, 2016 "Validation of Clinical Outcomes in Electronic Data Sources" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
- Nov, 2016 "Use of Automated Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
- Nov, 2016 "Case Studies in HIV and HCV Coinfection" American Conference for the Treatment of HIV Special Training for Effective Providers in HIV Webinar
- Dec, 2016 "Incidence and Risk Factors for End-Stage Liver Disease Among HIV/Hepatitis C-Coinfected Patients" University of Florida Department of Pharmaceutical Outcomes and Policy Grand Rounds, Gainesville, FL
- Dec, 2016 "Challenges in Access to Direct-Acting Antiviral Therapy for HCV: A Threat to HCV Elimination." Pennsylvania Department of Health Research Forum, Harrisburg, PA
- Dec, 2016 "HIV and Aging Mechanisms for Hepatocellular Cancer" Veterans Aging Cohort Study Scientific Meeting, Washington, DC

- Mar, 2017 "Drug-Induced Acute Liver Failure: A Concern for Clinicians?"
Department of Medicine Seminar, Princess Marina Hospital,
Gaborone, Botswana
- Mar, 2017 "Use of Automated Databases for Clinical Epidemiologic Research"
University of Botswana Research Seminar, Gaborone, Botswana
- Mar, 2017 "Epidemiology and Management of Chronic Hepatitis B in HIV"
Botswana HIV Clinicians Society Meeting, University of Botswana,
Gaborone, Botswana
- Apr, 2017 "HIV/Hepatitis C Virus Coinfection Management" American
Conference for the Treatment of HIV 2017, Dallas, TX
- Apr, 2017 "A National Strategy for the Elimination of Hepatitis B and C in the
US: Eliminating Hepatitis C Morbidity and Mortality" CDC
Foundation Summit for the Elimination of Hepatitis B and Hepatitis
C as Public Health Threats in the United States, Atlanta, GA
- Aug, 2017 "How to Manage a Pharmacoepidemiology-Based Research Team"
33rd International Conference on Pharmacoepidemiology &
Therapeutic Risk Management, Montreal, Canada
- Aug, 2017 "Establishing Productive Mentor-Mentee Relationships in
Pharmacoepidemiology" 33rd International Conference on
Pharmacoepidemiology & Therapeutic Risk Management, Montreal,
Canada
- Aug, 2017 "How to Manage a Pharmacoepidemiology-Based Research Team"
33rd International Conference on Pharmacoepidemiology &
Therapeutic Risk Management, Montreal Canada
- Oct, 2017 "Use of Automated Databases for Pharmacoepidemiology Research"
10th Asian Conference on Pharmacoepidemiology, University of
Queensland, Brisbane, Australia
- Oct, 2017 "Evaluation of Clinical Outcomes in Automated
Pharmacoepidemiology Databases" 10th Asian Conference on
Pharmacoepidemiology, University of Queensland, Brisbane,
Australia
- Oct, 2017 "Use of Pharmacoepidemiology Databases to Answer Clinically
Relevant Questions" 10th Asian Conference on
Pharmacoepidemiology, University of Queensland, Brisbane,
Australia
- Oct, 2017 "A National Strategy for the Elimination of Hepatitis B and C in the
US" Philadelphia Department of Public Health, Philadelphia, PA
- Nov, 2017 "Use of Automated Databases for Pharmacoepidemiologic
Research" FDA Introduction to Pharmacoepidemiologic Research
Methods, FDA White Oak Campus, Silver Spring, MD
- Jun, 2018 "Determinants of Hepatocellular Carcinoma Among HIV-Infected
Patients" Works in Progress Conference, VA Connecticut
Healthcare System/Yale School of Medicine, West Haven, CT
- Jun, 2018 "Overview of Pharmacoepidemiology Research Methods" 4th
Medicines Utilization Research in Africa (MURIA) Conference,
University of Namibia, Windhoek, Namibia

- Jun, 2018 "Cohort Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Case-Control Studies" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Statistical Test Selection in Epidemiologic Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Use of Automated Databases for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Evaluating Drug Exposure and Outcomes in Pharmacoepidemiology Databases" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Confounding and Bias in Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Jun, 2018 "Protocol Development for Pharmacoepidemiology Research" 4th Medicines Utilization Research in Africa (MURIA) Conference, University of Namibia, Windhoek, Namibia
- Aug, 2018 "Enhancing Creativity and Productivity in Pharmacoepidemiology" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic
- Aug, 2018 "How to Manage a Pharmacoepidemiology-Based Research Team" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic
- Aug, 2018 "Establishing Productive Mentor-Mentee Relationships in Pharmacoepidemiology" 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic
- Sep, 2018 "Epidemiology of End-Stage Liver Disease and Hepatocellular Carcinoma in HIV-Infected Persons" HIV and Liver Disease 2018 Meeting, Moran, WY
- Oct, 2018 "Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China
- Oct, 2018 "Evaluation of Clinical Outcomes in Automated Pharmacoepidemiology Databases" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China
- Oct, 2018 "Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology, Xi'an, China
- Aug, 2019 "How to Manage a Pharmacoepidemiology-Based Research Team" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA
- Sep, 2019 "How Do HIV, Risk Behaviors, and ART Influence Aging Syndromes?" NIH Workshop on HIV-Associated Comorbidities,

	Coinfections, and Complications, Bethesda, MD
Oct, 2019	"Use of Pharmacoepidemiology Databases to Answer Clinically Relevant Questions" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan
Oct, 2019	"Use of Healthcare Databases for Pharmacoepidemiology Research" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan
Oct, 2019	"Evaluation of Clinical Outcomes in Pharmacoepidemiology Databases" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan
Oct, 2019	"Validating Health Outcomes in Electronic Healthcare Databases: Methodology and Approaches in US Data Sources" 12th Asian Conference on Pharmacoepidemiology, Kyoto, Japan
Nov, 2019	"Use of Automated Databases for Pharmacoepidemiologic Research" FDA Introduction to Pharmacoepidemiologic Research Methods, FDA White Oak Campus, Silver Spring, MD
Feb, 2020	"Categorizing Drugs for Hepatotoxicity Potential by Evaluating Rates of Acute Liver Injury After Initiation of Use," VA Connecticut Healthcare System/Yale School of Medicine, West Haven, CT
Jun, 2020	"Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar
Jul, 2020	"Risk of Arterial and Venous Thrombotic Events With COVID-19: A Sentinel System Investigation - Update on Methods" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar
Aug, 2020	"Evaluation of Arterial and Venous Thrombotic Events With COVID-19 in the Sentinel System - Focus on Clinical Endpoints" Reagan-Udall Foundation for the US Food and Drug Administration, Webinar

Organizing Roles in Scientific Meetings:

Sep, 2010	Organizer and Moderator, "Therapies for Viral Hepatitis," Scientific Symposium, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Boston, MA
Aug, 2013	Organizer and Moderator "Challenges in Studying Drug-Induced Liver Injury in Pharmacoepidemiology Data Sources," Symposium 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Montreal, Canada
Sep, 2014	Moderator "Hepatitis and CMV: New and Noteworthy," Oral Abstract Session, 54th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC
Oct, 2014	Moderator "World War V: Viruses and Vaccines," Oral Abstract Session, 30th International Conference on Pharmacoepidemiology &

- Therapeutic Risk Management
Taipei, Taiwan
- May, 2015 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Ronald D. Wilcox, MD, "Viral Hepatitis" American Conference for the Treatment of HIV 2015
Dallas, TX
- Aug, 2015 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Boston, MA
- Aug, 2015 Moderator "Pharmacoepidemiology of Anti-Infectives and Steroids" Oral Abstract Session, 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Boston, MA
- May, 2016 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Ronald D. Wilcox, MD, "HIV/Hepatitis C Virus Coinfection" American Conference for the Treatment of HIV 2016
Dallas, TX
- Aug, 2016 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Dublin, Ireland
- Apr, 2017 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE, Margaret Hoffman-Terry, MD, and Ronald D. Wilcox, MD, "HIV/Viral Hepatitis Coinfection" American Conference for the Treatment of HIV 2017
Dallas, TX
- Apr, 2017 Scientific Organizing Committee Member, CDC Foundation Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States
Atlanta, GA
- Aug, 2017 Moderator, "Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease" Oral Abstract Session, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Montreal, Canada
- Aug, 2017 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Montreal, Canada
- Oct, 2017 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Wei Zhou, PhD, "Use of Automated Databases for Pharmacoepidemiology Research" 10th Asian Conference on

- Pharmacoepidemiology
University of Queensland, Brisbane, Australia
- Apr, 2018 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and H. Nina Kim, MD, MSc, "HIV/Viral Hepatitis Coinfection" American Conference for the Treatment of HIV 2018
Chicago, IL
- Jun, 2018 Organizer and Moderator, "Introduction to Pharmacoepidemiology" 4th Medicines Utilization Research in Africa (MURIA) Conference
University of Namibia, Windhoek, Namibia
- Aug, 2018 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Prague, Czech Republic
- Oct, 2018 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Wei Zhou, PhD, "Use of Automated Databases for Pharmacoepidemiology Research" 11th Asian Conference on Pharmacoepidemiology
Xi'an, China
- Apr, 2019 Organizer and Moderator, "HIV and Liver Disease" American Conference for the Treatment of HIV 2019
Miami, FL
- Aug, 2019 Chair, Scientific Program Committee, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Philadelphia, PA
- Aug, 2019 Organizer and Moderator, "Establishing a Successful Early Stage Career in Pharmacoepidemiology" Pre-Conference Educational Course, 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Philadelphia, PA
- Aug, 2019 Organizer and Moderator, "Keynote Session: The Role of Real-World Evidence in Regulatory Decision-Making" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Philadelphia, PA
- Aug, 2019 Organizer and Moderator, "Lightning Forum" 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Philadelphia, PA
- Nov, 2019 Co-Organizers and Co-Moderators, Vincent Lo Re, MD, MSCE and Sallie Pearson, PhD, "Use of Automated Databases for Pharmacoepidemiology Research" 12th Asian Conference on Pharmacoepidemiology
Kyoto, Japan
- Mar, 2020 Co-Moderators, Vincent Lo Re MD, MSCE and Naglaa H. Shoukry, BPharm, PhD, "Gone But Not Forgotten: HCV After Direct-Acting

Antiviral Therapy" Oral Abstract Session, Conference on
 Retroviruses and Opportunistic Infections 2020
 Boston, MA
 Aug, 2020 Organizer and Moderator, "HIV and Liver Disease" American
 Conference for the Treatment of HIV 2020
 Webinar

Bibliography:

Research Publications, peer reviewed (print or other media):

1. **Lo Re V 3rd**, Gasink L, Kostman, JR, Leonard D, Gross R: Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs 18(8): 436-42, August 2004.
2. Ende A, **Lo Re V 3rd**, DiNubile MJ, Mounzer K: Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDs 20(2): 75-8, February 2006.
3. Bisson GP, Frank I, Gross R, **Lo Re V 3rd**, Strom J, Wang X, Mogorosi M, Gaolathe T, Ndwapi N, Friedman H, Strom BL, Dickinson D: Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 20(9): 1333-6, June 2006.
4. **Lo Re V 3rd**, Schutte-Rodin S, Kostman JR: Obstructive sleep apnea among HIV patients. Int J STD AIDS 17(9): 614-20, September 2006.
5. Gross R, Yip B, **Lo Re V 3rd**, Wood E, Alexander C, Harrigan R, Bangsberg R, Montaner J, Hogg R: A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 194(8): 1108-14, October 2006.
6. **Lo Re V 3rd**, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44(3): 315-20, March 2007.
7. **Lo Re V 3rd**, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, Strom BL: Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol 60(3): 294-9, March 2007.
8. **Lo Re V 3rd**, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel B, Rennert H, Stieritz D, Putt M, Frank I, Strom BL: Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 44(3): 344-50, March 2007.
9. McComsey GA, **Lo Re V 3rd**, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I: Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected

subjects: a randomized, controlled study. Clin Infect Dis 46(8): 1290-6, April 2008.

10. **Lo Re V 3rd**, Wertheimer B, Localio AR, Kostman J, Dockter J, Linnen J, Giachetti C, Tebas P, Frank I, Strom BL, Gross R: Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol 43(1): 32-6, September 2008.
11. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, **Lo Re V 3rd**: Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 10(1): 25-32, January-February 2009.
12. **Lo Re V 3rd**, Amorosa VK, Localio R, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R: Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 48(2): 186-93, January 2009.
13. Butt AA, Tsevat J, Leonard AC, Shaikh OS, McMahon D, Khan UA, Dorey-Stein Z, **Lo Re V 3rd**: Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 13(4): 449-55, July 2009.
14. **Lo Re V 3rd**, Haynes K, Forde K, Localio AR, Schinnar R, Lewis JD: Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 18(9): 807-14, September 2009.
15. **Lo Re V 3rd**, Guaraldi G, Leonard MB, Lin J, Orlando G, Squillace N, Rochira V, Giovanni C, Kostman JR, Tebas P: Viral hepatitis coinfection is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 23(16): 2191-8, October 2009.
16. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, **Lo Re V 3rd**: The influence of abacavir and other antiretroviral agents on virologic response to hepatitis C virus therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 15(1): 91-9, February 2010.
17. DallaPiazza M, Amorosa VK, Localio AR, Kostman JR, **Lo Re V 3rd**: Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 10: 116, May 13 2010.
18. Szep Z, Guaraldi G, Shah SS, **Lo Re V 3rd**, Ratcliffe SJ, Orlando G, Carli F, Rossi R, Rochira V, Tebas P: Vitamin D deficiency is associated with type 2 diabetes mellitus among HIV-infected patients. AIDS 25(4): 525-9, February 2011.
19. Garla V, **Lo Re V 3rd**, Dorey-Stein Z, Kidwai F, Scotch M, Womack J, Justice A, Brandt C: The Yale cTAKES Extensions for Document Classification:

Architecture and application. J Am Med Inform Assoc 18(5): 614-20, May 2011.

20. **Lo Re V 3rd**, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Kidwai F, Brandt C, Dorey-Stein Z, Reddy KR, Justice AC: Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 20(7): 689-99, July 2011.
21. **Lo Re V 3rd**, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 155(6): 353-60, September 2011.
22. Lee I, Localio AR, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, Amorosa VK, **Lo Re V 3rd**: Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant 30(11): 1266-74, November 2011.
23. Park L, Tate J, Justice A, **Lo Re V 3rd**, Lim J, Bräu N, Brown S, Butt A, Gibert C, Goetz M, Rimland D, Rodriguez-Barradas M, Dubrow R: FIB-4 index predicts hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 20(12): 2512-7, December 2011.
24. Forde KA, Haynes K, Troxel A, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, **Lo Re V 3rd**: Risk of myocardial infarction associated with hepatitis C virus infection: A population-based cohort study. J Viral Hepat 19(4): 271-7, April 2012.
25. Goldberg DS, Lewis JD, Halpern SD, Weiner M, **Lo Re V 3rd**: Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 21(7): 765-9, July 2012.
26. Hernandez-Trujillo HS, Chapel H, **Lo Re V 3rd**, Notarangelo LD, Gathmann B, Grimbacher B, Boyle JM, Hernandez-Trujillo VP, Scalchunes C, Boyle ML, Orange JS: Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 169(1): 57-69, July 2012.
27. **Lo Re V 3rd**, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H, Strom BL: Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 21(11): 1202-15, November 2012.
28. **Lo Re V 3rd**, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman

- JR, Tebas P, Leonard MB, Localio AR: Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 56(5): 1688-98, November 2012.
29. Raphael BA, Dorey-Stein ZL, Lott J, Amorosa VK, **Lo Re V 3rd**, Kovarik C: Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol 67(5): 962-8, November 2012.
30. Goldberg DS, Lewis JD, Halpern SD, Weiner M, **Lo Re V 3rd**: Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 22(1): 103-7, January 2013.
31. **Lo Re V 3rd**, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 17(1): 94-103, January 2013.
32. Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, **Lo Re V 3rd**: Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol 47(5): 457-60, June 2013.
33. **Lo Re V 3rd**, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KBF, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A: Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf 8(22): 861-72, Aug 2013.
34. Edelman EJ, Gordon KS, **Lo Re V 3rd**, Skanderson M, Fiellin DA, Justice AC: Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf 22(12): 1352-6, December 2013.
35. Anderson JP, Tchetgen Tchetgen EJ, **Lo Re V 3rd**, Tate JP, Williams PL, Seage GR 3rd, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC: Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 58(5): 719-27, March 2014.
36. Keller SC, Momplaisir F, **Lo Re V 3rd**, Newcomb C, Liu Qing, Ratcliffe SJ, Long JA: Colorectal cancer incidence and screening in US Medicaid patients with and without HIV infection. AIDS Care 26(6): 716-22, March 2014.
37. **Lo Re V 3rd**, Kallan MJ, Tate J, AR Localio, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L,

Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.

38. Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, **Lo Re V 3rd**: Incidence and risk factors for incomplete hepatitis B virus DNA suppression in HIV/hepatitis B-coinfected patients receiving tenofovir-based antiretroviral therapy. J Viral Hepat 21(4): 288-96, Apr 2014.
39. Lim JK, Tate J, Fultz SL, Goulet JL, Rimland D, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Fiellin DA, Justice AC, **Lo Re V 3rd**: Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 58(10): 1449-58, May 2014.
40. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, **Lo Re V 3rd**: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol 61(2): 210-8, June 2014.
41. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, **Lo Re V 3rd**: Prevalence of diagnosed chronic hepatitis B infection among US Medicaid enrollees, 2000-2007. Ann Epidemiol 24(6): 418-23, June 2014.
42. Yehia BR, Schranz AJ, Umscheid CA, **Lo Re V 3rd**: The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One 9(7): e101554, July 2014.
43. **Lo Re V 3rd**, Wang L, Devine S, Baser O, Olufade T: Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis 59(7): 1027-31, October 2014.
44. Armah KA, Lim JK, **Lo Re V 3rd**, Baker J, Tracy R, Butt AA, Agan B, Rimland D, Justice AC, Freiberg MS: HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res 12(1): 50-59, December 2014.
45. Gowda C, Compher C, Amorosa VK, **Lo Re V 3rd**: Association between chronic hepatitis C virus infection and low muscle mass in U.S. adults. J Viral Hepat 21(12): 938-43, December 2014.
46. Cai B, Hennessy S, **Lo Re V 3rd**, Small DS: Epidemiologic research using

probabilistic outcome definitions. Pharmacoepidemiol Drug Saf 24(1): 19-26, January 2015.

47. Butt AA, Yan P, **Lo Re V 3rd**, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team: Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 175(2): 178-85, February 2015.
48. Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, **Lo Re V 3rd**, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM, Moore RD: Ascertainment and verification of end stage renal and liver disease outcomes in the North America AIDS Cohort Collaboration on Research and Design. AIDS Res Treat 2015: 923194, February 2015.
49. Ogdie AR, Pang WG, Forde KA, Bhangle SD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy KR, Schumacher HR, **Lo Re V 3rd**: Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord 16(19): 93, April 2015.
50. Saine ME, Carbonari DM, Newcomb CW, Nezamzadeh MS, Haynes K, Roy JA, Cardillo S, Hennessy S, Holick CN, Esposito DB, Gallagher AM, Bhullar H, Strom BL, **Lo Re V 3rd**: Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol 16(2): 8, April 2015.
51. Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, **Lo Re V 3rd**: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
52. **Lo Re V 3rd**, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Haynes K, Leidl KBF, Reddy KR, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 24(7): 676-83, July 2015.
53. **Lo Re V 3rd**, Kallan MJ, Tate J, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR: Predicting risk of end-stage liver disease in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. Open Forum Infect Dis 2(3): ofv109, July 2015.
54. Hernandez-Trujillo H, Orange JS, Roy JA, Wang Y, Newcomb CN, Liu Q, Hennessy

S, **Lo Re V 3rd**: Validity of primary immunodeficiency disease diagnoses in United States Medicaid data. J Clin Immunol 35(6): 566-572, August 2015.

55. Butt AA, Yan P, Shaikh OS, Freiberg MS, **Lo Re V 3rd**, Justice AC, Sherman KE: Virologic response and hematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 22(9): 691-700, September 2015.
56. Carbonari DM, Saine ME, Newcomb CW, Blak B, Roy JA, Haynes K, Wood J, Gallagher AM, Bhullar H, Cardillo S, Hennessy S, Strom BL, **Lo Re V 3rd**: Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf 24(9): 999-1003, September 2015.
57. **Lo Re V 3rd**, Lynn K, Stumm E, Long J, Nezamzadeh MS, Baker JF, Kapalko A, Mounzer K, Tebas P, Kostman JR, Leonard MB: Structural bone deficits in HIV/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected women. J Infect Dis 212(6): 924-33, September 2015.
58. Gowda C, McKittrick N, Kim D, Kappes R, **Lo Re V 3rd**, Tebas P: Obesity is not associated with impaired immune response to influenza vaccination in HIV-infected persons. AIDS Res Treat 2015: Article ID 653840, October 2015.
59. Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, **Lo Re V 3rd**: Increased risk of hip fracture associated with dually-treated HIV/hepatitis B virus coinfection. J Viral Hepat 22(11): 936-47, November 2015.
60. **Lo Re V 3rd**, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KBF, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA: Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy's Law and a new prognostic model. Clin Gastroenterol Hepatol 13(13): 2360-8, December 2015.
61. **Lo Re V 3rd**, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Haynes K, Roy JA, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA: Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 129(3): 283-91, e5, March 2016.
62. Rogal SS, Yan P, Rimland D, **Lo Re V 3rd**, Al-Rowais H, Fried L, Butt AA: Incidence and progression of chronic kidney disease after hepatitis C seroconversion: Results from ERCHIVES. Dig Dis Sci 61(3): 930-6, March 2016.
63. Bhattacharya D, Tseng CH, Tate JP, **Lo Re V 3rd**, Gibert C, Butt A, Brown S, Lim JK, Rodriguez-Barradas MC, Rimland D, Kaufman E, Justice AC, Goetz MB:

Isolated hepatitis B core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection. J Acquir Immune Defic Syndr 72(1): e14-17, May 2016.

64. **Lo Re V 3rd**, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR: Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 14(7): 1035-4, July 2016.
65. Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, **Lo Re V 3rd**, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas M, Fiellin LE, Bryant K, Justice AC, Fiellin DA: Hepatic safety of buprenorphine in HIV-infected and uninfected patients with opioid use disorder: The role of HCV infection. J Subst Abuse Treat 68: 62-7, September 2016.
66. Gowda C, Brown TT, Compher C, Forde KA, Kostman JR, Shaw P, Tien PC, **Lo Re V 3rd**: Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS 30(16): 2519-28, October 2016.
67. Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, **Lo Re V 3rd**, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice AC, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.: Risk of end-stage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 63(9): 1160-7, November 2016.
68. Gowda C, Carbonari DM, Forde KA, Goldberg DS, Lewis JD, Reddy KR, Roy JA, Carey M, Liu J, Marks AR, Schneider JL, Corley DA, **Lo Re V 3rd**: Risk of acute liver injury with antiretroviral therapy by viral hepatitis status. Open Forum Infect Dis 4(2): ofx012, January 2017.
69. Lum KJ, Newcomb CW, Roy JA, Carbonari DM, Saine ME, Cardillo S, Bhullar H, Gallagher AM, **Lo Re V 3rd**: Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol 73(1): 115-123, January 2017.
70. Gowda C, Sheikh U, Maier A, Chang KM, Kaplan DE, **Lo Re V 3rd**, Amorosa VK: Identifying barriers and potential strategies to improve hepatocellular carcinoma surveillance for HBV-infected Veterans. Fed Pract 34 (Suppl 4): S20-29, June 2017.
71. Butt AA, Ren Y, **Lo Re V 3rd**, Taddei TH, Kaplan DE: Comparing Child-Pugh, MELD and FIB-4 to predict clinical outcomes in HCV-infected persons: Results

from ERCHIVES. Clin Infect Dis 65(1): 64-72, July 2017.

72. Taylor BS, So-Armah, Tate JP, Marconi VC, Koethe J, Bedimo R, Butt AA, Gibert CL, Goetz MB, Rodriguez-Barradas MC, Womack JA, Gerschenson M, **Lo Re V 3rd**, Rimland D, Yin MT, Leaf D, Tracy RP, Justice AC, Freiberg MS: HIV and obesity comorbidity increases interleukin 6 but not soluble CD14 or D-dimer. J Acquir Immune Defic Syndr 75(5): 500-508, July 2017.
73. **Lo Re V 3rd**, Carbonari DM, Saine ME, Newcomb CW, Roy JA, Liu Q, Wu Q, Cardillo S, Haynes K, Kimmel SE, Reese PP, Margolis DJ, Apter AJ, Reddy KR, Hennessy S, Bhullar H, Gallagher AM, Esposito DB, Strom BL: Post-authorization safety study of the DPP-4 inhibitor saxagliptin: A large-scale multi-national family of cohort studies of five outcomes. BMJ Open Diabetes Res Care 5: e000400, August 2017.
74. Coppock D, Zambo D, Moyo D, Tanthuma G, Chapman J, **Lo Re V 3rd**, Graziani A, Lowenthal E, Hanrahan N, Littman-Quinn R, Kovarik C, Albarracin D, Holmes JH, Gross R: Development and usability of a smartphone application for tracking antiretroviral medication refill data for human immunodeficiency virus. Methods Inf Med 56(5): 351-359, September 2017.
75. Byrne DD, Tate JP, Forde KA, Kostman JA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, **Lo Re V 3rd**: Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic hepatitis C virus infection status. Clin Infect Dis 65(9): 1542-50, October 2017.
76. **Lo Re V 3rd**, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Kostman JR, Gross R, Justice AC, Roy JA: Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf 26(10): 1172-1181, October 2017.
77. So-Armah KA, Lim JK, **Lo Re V 3rd**, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi V, Goetz MB, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS: FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology 66(4): 1286-1295, October 2017.
78. Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün K, Gibert C, **Lo Re V 3rd**, Rimland D, Womack J, Wyatt CM, Tate JP: Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 32(6): 739-49, March 2018.
79. Kushner T, Shaw PA, Kalra A, Magaldi LN, Monpara P, Bedi G, Krok K, Centkowski S, Dalldorf K, D'Souza J, Halegoua-De Marzio D, Goldberg DS, Levine LD, Srinivas SK, Lewis JD, Forde KA, **Lo Re V 3rd**: Incidence,

determinants, and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. Liver Int 38(5): 813-20, May 2018.

80. Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, **Lo Re V 3rd**: Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: A national specialty pharmacy cohort study. Open Forum Infect Dis 5(6): ofy076, June 2018.
81. Li DK, Ren Y, Fierer DS, Rutledge S, Saikh OS, **Lo Re V 3rd**, Simon T, Abou-Samra A, Chung RT, Butt AA: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 67(6): 2243-53, June 2018.
82. Roy J, Lum KJ, Dworkin JD, **Lo Re V 3rd**, Daniels MJ: Bayesian nonparametric generative models for causal inference with missing at random covariates. Biometrics 74: 1193-1202, July 2018.
83. Saine ME, Gizaw M, Carbonari DM, Newcomb CW, Roy JA, Cardillo S, Esposito DB, Bhullar H, Gallagher AM, Strom BL, **Lo Re V 3rd**: Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf 27(10): 1147-1150, October 2018.
84. Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert C, **Lo Re V 3rd**, Fiellin DA, Justice AC, Tate JP: Provider verification of electronic health record receipt and non-receipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Ann Epidemiol 28(11): 808-811, November 2018.
85. Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, **Lo Re V 3rd**, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Pallella Jr. F, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ: Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: A collaboration of cohort studies. Lancet HIV 6(2): e93-e104, February 2019.
86. Butt AA, Yan P, **Lo Re V 3rd**, Shaikh OS, Ross DB: Trends in treatment uptake and provider specialty for HCV infection in the VA healthcare system: Results from ERCHIVES. Clin Infect Dis 68(5): 857-859, February 2019.
87. Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, **Lo Re V 3rd**: Comparison of the prevalence, severity, and risk factors for hepatic steatosis in

HIV-infected and uninfected people. BMC Gastroenterol 19(1): 52, April 2019.

88. Sawinski D, Forde KA, **Lo Re V 3rd**, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP: Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: A retrospective cohort study. Am J Kidney Dis 73(6): 815-826, June 2019.
89. **Lo Re V 3rd**, Newcomb CW, Carbonari DC, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim, JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN: Determinants of liver complications among HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 82(1): 71-80, September 2019.
90. Zeldow B, **Lo Re V 3rd**, Roy J: A semiparametric modeling approach using Bayesian Additive Regression Trees with an application to evaluate heterogeneous treatment effects. Ann Appl Stat 13(3): 1989-2010, September 2019.
91. Saine ME, Carbonari DM, Newcomb CW, Gallagher AM, Blak BT, Roy JA, Wood J, Cardillo S, Hennessy S, Strom BL, **Lo Re V 3rd**: Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral anti-diabetic therapies. Pharmacoepidemiol Drug Saf 28(10): 1328-35, October 2019.
92. Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richard KA, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, **Lo Re V 3rd**: Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 29(1): 71-78, January 2020.
93. Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, **Lo Re V 3rd**: Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 15(2): e0228471, February 2020.
94. So-Armah KA, Lim JK, **Lo Re V 3rd**, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi V, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS: FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Prog Cardiovasc Dis 63(2): 184-91, March 2020.
95. Baker JF, Leonard CE, **Lo Re V 3rd**, Weisman MH, George MD, Kay J: Biosimilar

- uptake in the academic and Veterans Health Administration settings: Influence of institutional incentives. Arthritis Rheumatol 72(7): 1067-71, July 2020.
96. Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, **Lo Re V 3rd**, Justice AC: Excess weight gain after cure of hepatitis C infection with direct-acting antivirals. J Gen Intern Med 35(7): 2025-2034, July 2020.
97. Rhodes JM, **Lo Re V 3rd**, Mato AR, Chong EA, Barrientos JC, Gerson JN, Barta SK, Landsburg DJ, Nasta SD, Svoboda J, Loren AW, Schuster SJ: Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: Incidence and impact on clinical outcomes. Clin Lymphoma Myeloma Leuk 20(7): 438-44, July 2020.
98. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, **Lo Re V 3rd**: HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst 112(7): 747-755, July 2020.
99. Butt AA, Yan P, Shaikh OS, **Lo Re V 3rd**, Abou-Samra AB, Sherman KE: Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. J Hepatol 73(2): 277-284, August 2020.
100. Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, **Lo Re V 3rd**: Determinants of stigma among patients with hepatitis C virus (HCV) infection. J Viral Hepat Page: In Press. August 2020.
101. Wang W, **Lo Re V 3rd**, Guo Y, Xiao H, Brown J, Park H: Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus infected patients in the U.S. Aliment Pharmacol Ther Page: In Press. August 2020.
102. van Boemmel-Wegmann S, **Lo Re V 3rd**, Park H: Treatment uptake and cost burden of hepatitis C (HCV) therapies among HCV patients with a particular focus on HIV coinfection. Dig Dis Sci Page: In Press. August 2020.
103. Gelfand JM, Armstrong AW, Bell S, Anesi G, Blauvelt A, Calabrese, C, Dommasch E, Feldman SR, Gladman D, Kircik L, Lebwohl M, **Lo Re V 3rd**, Martin G, Merola J, Scher J, Schwartzman S, Treat J, Van Voorhees A, Ellebrecht C, Fenner J, Ocon A, Syed M, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin, CR: National Psoriasis Foundation COVID-19 Task Force Guidance for the Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol Page: In Press. September 2020.
104. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH,

Justice AC, **Lo Re V 3rd**: Accuracy of FIB-4 for cirrhosis in people living with HIV and hepatocellular carcinoma. J Acquir Immune Defic Syndr Page: In Press. September 2020.

Research Publications, peer-reviewed reviews:

1. **Lo Re V 3rd**, Brennan PJ, Wadlin J, Weaver R, Nachamkin I: Infected branchial cleft cyst due to *Bordetella bronchiseptica* in an immunocompetent patient. J Clin Microbiol 39(11): 4210-2, November 2001.
2. **Lo Re V 3rd**, Gluckman SJ: Eosinophilic meningitis due to *Angiostrongylus cantonensis* in a returned traveler: case report and review of the literature. Clin Infect Dis 33(9): e112-5, November 2001.
3. **Lo Re V 3rd**, Bellini LM: William of Occam and Occam's razor. Ann Intern Med 136(8): 634-5, April 2002.
4. **Lo Re V 3rd**, Gluckman SJ: Eosinophilic meningitis due to *Gnathostoma spinigerum*. J Infect 45(2): 117-20, August 2002.
5. **Lo Re V 3rd**, Gluckman SJ: Eosinophilic meningitis. Am J Med 114(3): 217-23, February 2003.
6. **Lo Re V 3rd**, Fishman NO, Nachamkin I: Recurrent catheter-related *Rhodotorula rubra* infection. Clin Microbiol Infect 9(8): 897-900, August 2003.
7. **Lo Re V 3rd**, Gluckman SJ: Prevention of malaria in travelers. Am Fam Phys 68(3): 509-14, August 2003.
8. **Lo Re V 3rd**, Fox KR, Ferrari VA, Scott CH, Kossev PM, Kostman JR: Hypereosinophilia associated with cardiac rhabdomyosarcoma. Am J Hematol 74(1): 64-7, September 2003.
9. **Lo Re V 3rd**, Gluckman SJ: Fever in the returned traveler. Am Fam Phys 68(7): 1343-50, October 2003.
10. **Lo Re V 3rd**, Occi JL, MacGregor RR: Identifying the vector of Lyme disease. Am Fam Phys 69(8): 1935-7, Apr 2004.
11. **Lo Re V 3rd**, Gluckman SJ: Travel immunizations. Am Fam Phys 70(1): 89-99, July 2004.
12. **Lo Re V 3rd**, Kostman JR: Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Reader 14(10): 555-7, 562, 565-71, October 2004.
13. **Lo Re V 3rd**, Kostman JR: Management of chronic hepatitis C. Postgrad Med J 81(956): 376-82, June 2005.

14. Samaha F, Ky B, **Lo Re V 3rd**: Type III hyperlipoproteinemia unmasked by HIV antiretroviral therapy. Am J Med 118(6): 691-2, June 2005.
15. **Lo Re V 3rd**, Bellini LM: William Pepper Jr, MD (1843-1898): portrait of a nineteenth-century medical educator. J Med Biogr 14(3): 169-77, August 2006.
16. **Lo Re V 3rd**, Strom BL: The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. Pharmacoepidemiol Drug Saf 16(7): 818-25, July 2007.
17. Dorey-Stein Z, Amorosa VK, Kostman JR, **Lo Re V 3rd**, Shannon RP: Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr 3: 111-4, March 2008.
18. **Lo Re V 3rd**, Kostman JR, Amorosa VK: Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 12(3): 587-609, August 2008.
19. Bedimo R, Maalouf NM, **Lo Re V 3rd**: Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS 11(3): 285-93, May 2016.
20. Taddei TH, **Lo Re V 3rd**, Justice AC: HIV, aging, and viral coinfections: Taking the long view. Curr HIV/AIDS Rep 13(5): 269-78, September 2016.
21. Midgard H, Weir A, Palmateer N, **Lo Re V 3rd**, Pineda JA, Macías J, Dalgard O: HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 65: S33-45, October 2016.
22. Gowda C, **Lo Re V 3rd**: Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep 17: 111-20, June 2018.
23. Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, **Lo Re V 3rd**, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA: Hepatitis C Guidance 2019 Update: AASLD-IDS recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology Page: In Press. February 2020.

Contributions to peer-reviewed research publications, participation cited but not by authorship:

1. Leake JA, Mosley DG, England B, Graham JV, Plikaytis BD, Ampel NM, Perkins BA, Hajjeh RA: Risk factors for acute symptomatic coccidioidomycosis among

elderly persons in Arizona, 1996-1997. J Infect Dis 181: 1435-40, April 2000.

Research Publications, non-peer reviewed:

[none]

Abstracts (Last 3 years):

1. Marconi VC, So-Armah K, Tate JP, Lim JK, **Lo Re V 3rd**, Butt AA, Goetz MB, Rodriguez-Barradas M, Justice AC, Freiberg M: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV- individuals. Conference on Retroviruses and Opportunistic Infections 2017, Seattle, WA February 2017 Notes: Oral Abstract 986.
2. Torgersen J, So-Armah K, Freiberg M, Budoff M, Lim JK, Butt AA, Rodriguez-Barradas M, Justice AC, Kostman JK, **Lo Re V 3rd**: Prevalence and risk factors for hepatic steatosis in HIV+ persons. Conference on Retroviruses and Opportunistic Infections 2017, Seattle, WA February 2017 Notes: Poster presentation Abstract 333.
3. Li DK, Ren Y, Saikh OS, Fierer D, **Lo Re V 3rd**, Abou-Samra AB, Chung R, Butt AA: The incidence of hepatocellular carcinoma is not increased in individuals after treatment with interferon-free regimens: an ERCHIVES study. ID Week 2017, San Diego, CA October 2017 Notes: Poster presentation Abstract 64061.
4. Torgersen J, Carbonari DM, Kallan M, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Park L, Kidwai-Khan F, Taddei T, Justice AC, **Lo Re V 3rd**: Advanced stage of hepatocellular carcinoma is more common among HCV uninfected US Veterans. 16th International Conference on Malignancies in HIV/AIDS, Bethesda, MD October 2017 Notes: Poster presentation Abstract 03.
5. Li DK, Ren Y, Fierer DS, Rutledge S, Saikh OS, **Lo Re V 3rd**, Abou-Samra A, Chung RT, Butt AA: The incidence of hepatocellular carcinoma is not increased in individuals with chronic hepatitis C after SVR with interferon-free regimens compared with interferon-containing regimens: An ERCHIVES study. The Liver Meeting 2017, Washington DC. Oral Abstract 2767638, November 2017.
6. Torgersen J, Carbonari DM, Kallan M, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Park LS, Kidwai-Khan F, Taddei T, Justice A, **Lo Re V 3rd**: Impact of HIV and chronic HCV status on advanced HCC stage in Veterans. The Liver Meeting 2017, Washington DC November 2017 Notes: Poster presentation Abstract 1427.
7. Benson EA, Klein MB, Kitahata MM, Moore RD, **Lo Re V 3rd**, Horberg MA, Mayor A, Silverberg MJ, Kim HN, Eron JJ, Cachay ER, Hull M, Gange SJ, Althoff KN: Survival after end-stage liver disease in adults with HIV: Data from the NA-ACCORD. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 624.

8. Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick PN, **Lo Re V 3rd**: Increasing incidence of denial of DAA therapy for chronic HCV by insurance type. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 600.
9. **Lo Re V 3rd**, Newcomb CW, Carbonari DM, Roy JA, Kitahata MM, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Hull M, Moore RD, Klein MB, Kim HN: Determinants of liver complications among HIV/hepatitis B-coinfected patients. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 620.
10. Park LS, Justice AC, **Lo Re V 3rd**, Mehta R, Carbonari D, Torgerson J, D'Addeo K, Richards KM, Zhang X, Taddei T: Tissue collection to examine HIV and HCV mechanisms for hepatocellular carcinoma. 22nd International Workshop on HIV and Hepatitis Observational Databases, Fuengirola, Spain March 2018 Notes: Poster presentation Abstract 63.
11. Torgersen J, Park LS, Taddei T, Carbonari DM, Kallan MJ, Mitchell-Richards K, Zhang X, D'Addeo K, Mehta R, Kidwai-Khan F, Justice A, **Lo Re V 3rd**: Presentation and outcome of biopsy-proven hepatocellular carcinoma by HIV status. Conference on Retroviruses and Opportunistic Infections 2018, Boston, MA March 2018 Notes: Poster presentation Abstract 226.
12. Wang W, **Lo Re V 3rd**, Xiao H, Brown J, Guo Y, Park H: Incidence of hepatocellular carcinoma and extrahepatic cancers among HCV-infected patients in the era of direct-acting antivirals. International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Baltimore, MD, USA May 2018 Notes: Oral Abstract IN3.
14. Rentsch CT, Esserman DA, Cartwright EJ, Tate JP, Fiellin DA, Justice AC, **Lo Re V 3rd**: Receipt and virologic outcomes of HCV direct-acting antivirals by alcohol use and HIV status. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic August 2018 Notes: Poster presentation Abstract 199.
15. Saine ME, Barg FK, Carbonari DM, Gross R, **Lo Re V 3rd**: Barriers and facilitators to initiating and completing direct-acting antiviral therapy for chronic hepatitis C infection. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic August 2018 Notes: Poster presentation Abstract 1052.
16. Saine ME, Carbonari DM, Newcomb CW, Roy JA, Wood J, Gallagher AM, Cardillo S, Hennessy S, Strom BL, **Lo Re V 3rd**: Concordance of hospitalizations within the Clinical Practice Research Datalink (CPRD) & Hospital Episode Statistics

(HES) among patients treated with oral antidiabetic therapies 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic August 2018 Notes: Poster presentation Abstract 186.

17. Wang W, **Lo Re V 3rd**, Xiao H, Brown J, Guo Y, Park H: Direct-acting antivirals reduce the risk of non-hepatic cancers among HCV-infected patients. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic August 2018 Notes: Poster presentation Abstract 848.
18. Butt AA, Yan P, **Lo Re V 3rd**, Shaikh OS, Ross DB: Treatment update for hepatitis C virus infection in the Veterans Affairs healthcare system in the era of directly acting antiviral agents: An ERCHIVES study. ID Week 2018, San Francisco, CA October 2018 Notes: Poster abstract presentation 2219.
19. Butt AA, Yan P, **Lo Re V 3rd**, Shaikh OS, Ross DB: Trends in treatment uptake and provider specialty for HCV infection in the VA healthcare system in the era of directly acting antiviral agents: An ERCHIVES study. The Liver Meeting 2018, San Francisco, CA November 2018 Notes: Poster presentation Abstract 1575.
20. Kim HN, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Cachay ER, Horberg MA, Moore RD, Kitahata MM, Klein MB, **Lo Re V 3rd**: Clinical predictors of hepatocellular carcinoma among HIV/chronic hepatitis B coinfecting patients in the NA-ACCORD. The Liver Meeting 2018, San Francisco, CA November 2018 Notes: Poster presentation Abstract 2087.
21. Krishnan S, Akgun KM, Tate JP, Bryant K, Crystal S, **Lo Re V 3rd**, Rentsch C, Crothers K, Gordon K, Oursler KA, Justice AC: Neurocognitively-acting potentially inappropriate medications, alcohol, and delirium among patients with and without HIV. 23rd International Workshop on HIV and Hepatitis Observational Databases, Athens, Greece March 2019 Notes: Poster presentation Abstract 245.
22. Marquez LK, Chaillon A, Soe KP, Johnson D, Zosso JM, Incerti A, Loarec A, Nguyen A, Walker J, Mafirakureva N, **Lo Re V 3rd**, Wynn A, Vickerman P, Martin NK: Cost-effectiveness of HCV treatment among HIV-positive individuals in Myanmar. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Poster presentation Abstract 590.
23. Torgersen J, Kallan MJ, Carbonari DM, Roy JA, Park LS, Taddei T, Mehta R, D'Addeo K, Lim JK, Goetz MB, Tate JP, Bräu N, Justice AC, **Lo Re V 3rd**: HIV viremia and low CD4+ count increase HCC risk in those without advanced liver fibrosis. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Oral Abstract 90.
24. Zola C, Duncan MS, So-Armah K, Crothers K, Butt AA, Gibert CL, Lim JK, **Lo Re**

- V 3rd**, Tindle HA, Freiberg MS, Brittain EL: HIV/HCV-specific markers and echocardiographic pulmonary artery systolic pressure. Conference on Retroviruses and Opportunistic Infections 2019, Seattle, WA March 2019 Notes: Poster presentation Abstract 659.
25. Binkley A, Torgersen J, Gilmore J, O'Neal J, Saine ME, Russell R, Short W, **Lo Re V 3rd**: Elimination of hepatitis C virus in HIV-coinfected patients in a viral hepatitis center: A multi-disciplinary approach. 13th American Conference for the Treatment of HIV, Miami, FL April 2019 Notes: Poster presentation Abstract 6.
26. Wang W, **Lo Re V 3rd**, Guo Y, Xiao H, Brown J, Park HS: The clinical and economic impact of HCV treatment on non-hepatic cancers among HCV-infected patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019, New Orleans, LA May 2019 Notes: Oral Abstract 92677.
27. Wang W, **Lo Re V 3rd**, Guo Y, Xiao H, Brown J, Park HS: The increased risks of non-hepatic cancers among hepatitis C virus (HCV)-infected patients: A population-based cohort study in the US. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019, New Orleans, LA May 2019 Notes: Oral Abstract 92652.
28. Saine ME, Szymczak JE, **Lo Re V 3rd**: A conceptual model to evaluate disease-related stigma and access to healthcare among patients with hepatitis C virus infection 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA August 2019 Notes: Poster presentation Abstract 1009.
29. Rhodes J, Mato A, Hubbard R, Chong E, Winchell N, Kennard K, Nasta S, Landsburg D, Gerson J, Bartta S, Svoboda J, Loren A, **Lo Re V 3rd**, Schuster S: Characteristics and outcomes of ibrutinib-associated musculoskeletal toxicities in CLL patients. International Workshop on CLL, Edinburgh, Scotland September 2019 Notes: Oral Abstract 1990.
30. Butt AA, Yan P, Aslam S, **Lo Re V 3rd**, Shaikh O: Reduction in liver-related mortality among HCV-Infected persons is driven by attainment of SVR independent of the regimen used: Results from the ERCHIVES cohort. ID Week 2019, Washington DC October 2019 Notes: Oral Abstract 676567.
31. Sun J, Althoff KN, Kim HN, Kitahata MM, Achenbach CJ, D'Souza G, Klein MB, Lau B, Lim JK, **Lo Re V 3rd**, Marcus JL, Mayor AM, Silverberg MJ, Kirk GD: Hepatocellular carcinoma risk among persons with HIV in North America, 1996-2015. Conference on Retroviruses and Opportunistic Infections 2020, Boston, MA March 2020 Notes: Oral Abstract 3009.
32. Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta R, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH,

Justice AC, **Lo Re V 3rd**: Accuracy of FIB-4 for cirrhosis in HIV+ patients with hepatocellular carcinoma. Conference on Retroviruses and Opportunistic Infections 2020, Boston, MA March 2020 Notes: Poster presentation Abstract 2428.

33. Bykov K, Li H, Kim S, **Lo Re V 3rd**, Gagne JJ: Drug-drug interaction surveillance study: Comparing self-controlled designs in five empirical examples in real-world data 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting September 2020 Notes: Poster presentation Abstract PO-2406.
34. Saine ME, Szymczak JE, Barg FK, **Lo Re V 3rd**: Stigma as a barrier to the hepatitis C virus continuum Of care in the era of direct-acting antiviral therapies. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting September 2020 Notes: Poster presentation Abstract PO-4442.
35. Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, **Lo Re V 3rd**: Determinants of stigma among patients with hepatitis C virus (HCV) infection. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting September 2020 Notes: Poster presentation Abstract MYPO-05.
36. Torgersen J, Newcomb CW, Carbonari DM, Rentsch C, Park L, Mehta R, D'Addeo K, Taddei T, Justice AC, **Lo Re V 3rd**: Risk of acute liver injury with protease inhibitor-based antiviral therapy for hepatitis C. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - All Access Virtual Meeting September 2020 Notes: Poster presentation Abstract PO-4654.
37. Saine ME, Szymczak JE, Forde KA, Moore TM, Bamford LP, Barg, FK, Schnittker J, Holmes JH, Mitra N, **Lo Re V 3rd**: The impact of hepatitis C-related knowledge on perceptions of stigma among infected individuals. ID Week 2020, Virtual Meeting October 2020 Notes: Poster presentation Abstract 911151.
38. Mezochow A, Torgersen J, Newcomb CW, Carbonari DM, Hennessy S, Park LS, Mehta RL, Tate JP, Taddei TH, Justice AC, **Lo Re V 3rd**: Risk of severe acute liver injury among initiators of potentially hepatotoxic drugs. Liver Meeting Digital Experience 2020 November 2020 Notes: Oral Abstract 119.
39. Park LS, Zhang X, Nalbantoglu I, Kidwai-Khan F, Mehta RL, Carbonari DC, Torgersen J, **Lo Re V 3rd**, Justice AC, Taddei TH: A histological resource to examine HIV and aging mechanisms for hepatocellular carcinoma. Liver Meeting Digital Experience 2020 November 2020 Notes: Poster presentation Abstract 1030.

Editorials, Reviews, Chapters, including participation in committee reports (print or other

media):

1. **Lo Re V 3rd**, Barton T, Feiner S: A pain in the back [Letter] N Engl J Med 344(6): 456, February 2001.
2. **Lo Re V 3rd**, Fishman NO: Recognition and management of anthrax [Letter] N Engl J Med 346(12): 943-5, March 2002.
3. **Lo Re V 3rd**, Kostman JR: Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C [Letter] Clin Infect Dis 38(12): 1789-90, June 2004.
4. **Lo Re V 3rd**: Economic analysis of hepatitis B screening and treatment. Clin Infect Dis 52(11): 1307-1309, June 2011.
5. **Lo Re V 3rd**, Reddy KR: Hepatobiliary complications of HIV. Handbook of Liver Disease, 3rd Edition. Friedman LS, Keeffe EB (eds.). Elsevier, 2012.
6. **Lo Re V 3rd**, Tate JP, Lim JK, Fiellin DA, Justice AC: Reply to Marcellin et al. Clin Infect Dis 59(8): 1192-3, October 2014.
7. Justice AC, Freiberg MS, **Lo Re V 3rd**: Should everyone aging with HIV take a statin? Lancet HIV 2(2): e36-e37, February 2015.
8. **Lo Re V 3rd**, Schuster M: Evaluating hepatitis B virus reactivation during solid tumor chemotherapy: Evidence to guide pretreatment hepatitis B screening and prophylaxis. Ann Intern Med 164(1): 64-65, January 2016.
9. National Academies of Sciences, Engineering, and Medicine. 2016: Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press April 2016 Notes: doi: 10.17226/23407.
10. **Lo Re V 3rd**, Forde KA, Lewis JD, Goldberg DS, Carbonari DM, Roy JA, Reddy KR, Sha D, Strom BL, Corley DA: Reply: Is Sensitivity the Key Measure to Predict Acute Liver Failure in Drug-Induced Liver Injury Patients? Clin Gastroenterol Hepatol 14(6): 918-919, June 2016 Notes: Is sensitivity the key measure to predict acute liver failure in drug-induced liver injury patients? [Letter]
11. **Lo Re V 3rd**: Extrahepatic complications of hepatitis C virus infection in HIV and the impact of successful antiviral treatment. Clin Infect Dis 64(4): 498-500, February 2017.
12. **Lo Re V 3rd**, Carbonari DM, Lewis JD, Roy JA, Corley DA.: Reply: Effects of Treatment with Azoles Are Overstated. Am J Med 130(8): e369, August 2017.
13. **Lo Re V 3rd**: Is moderate alcohol consumption safe for HIV/hepatitis C

virus-coinfected women? Clin Infect Dis 65(12): 2057-59, November 2017.

14. **Lo Re V 3rd**, Reddy KR: Hepatobiliary complications of HIV. Handbook of Liver Disease, 4th Edition. Friedman LS, Martin P (eds.). Elsevier, 2017.

Books:

1. Infectious Diseases Hot Topics. **Lo Re V 3rd** (ed.). Hanley & Belfus, 2004.

Alternative Media:

1. **Lo Re V 3rd**, Gluckman SJ: Eosinophilic meningitis. MD Consult Infectious Disease. MD Consult, April 2002.
2. **Lo Re V 3rd**: Principal agents of bioterrorism: recognition and management. Psychiatric Times 22(14): 40, December 2005.
3. **Lo Re V 3rd**: Addressing anticipated adherence problems prior to hepatitis C virus treatment. Hepatitis C Online (<http://www.hepatitisc.uw.edu>). August 2013.
4. Gowda C, **Lo Re V 3rd**: What's behind fatigue, elevated liver enzymes? The Philadelphia Inquirer June 2015 Notes: June 28, 2015.
5. **Lo Re V 3rd**: Access to Direct-Acting Antiviral Therapy for Chronic HCV: Any Progress? AGA Perspectives (<http://agaperspectives.gastro.org/>) November 2016.

Patents:

[none]

Research Support:

Ongoing Research Support

1. R01-CA206465 (Multiple PI: **Lo Re**; Justice) 07/01/16 – 05/31/21
HIV and Aging Mechanisms for Hepatocellular Cancer

This grant utilizes the unique data of the Veterans Aging Cohort Study to conduct a series of epidemiologic and pathologic analyses to discover how factors specific to aging with HIV infection interact with conditions associated with liver injury in the general population for the development of hepatocellular carcinoma.

2. R01-AI136626 (PI: **Lo Re**) 12/01/17 – 11/30/22
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy
This study will assemble 3 cohorts: 1) HIV/HCV patients initiating direct-acting antiviral (DAA) therapy, 2) HCV patients initiating DAAs, and 3) uninfected persons. Aim 1 will compare muscle mass/strength; fat; bone quality; and insulin resistance across the cohorts at enrollment. Aim 2 will examine changes in these outcomes in coinfecting and HCV only patients from DAA initiation to 12 months after HCV cure (18 months) and compare to changes in uninfected persons over 18 months.

3. R01-AR076392 (PI: Rajapakse; Co-Investigator: **Lo Re**) 09/11/19 – 07/31/24

MRI Assessment of Hip Fracture Risk and Therapy Response in HIV/HCV Coinfection

This study will apply novel magnetic resonance imaging (MRI) methods to the proximal femur (i.e., hip) in the above three cohorts (in R01-AI136626 [PI, Lo Re]) in order to determine how MRI analyzes bone deficits inaccessible by BMD/FRAX scores, how the methodology may provide clinical tools useful for future HIV+/HCV+ trials, and how direct-acting antiviral (DAA) treatment of HCV affects bone strength in light of possible future treatment innovations for fracture risk in HIV+/HCV+ and HCV+ patients.

4. R01-DE029648-01 (PI: Omolehinwa; Co-Investigator: **Lo Re**) 04/01/20 – 03/31/25
Impact of Oral Health on Metabolism and Inflammation in HIV Patients on Antiretroviral Therapy

This proposal represents an interdisciplinary and collaborative effort between dental and medical experts that seeks to improve outcomes for HIV-infected persons by prospectively evaluating oral-systemic non-AIDS-associated comorbid diseases (NCDs) in HIV patients who have been on ART for at least one year. Results from the study will lead to a better understanding of key oral health manifestations among persons with HIV and their impact on the development and severity of NCDs. Better understanding the interplay of oral and systemic inflammation in HIV-infected persons on ART can improve oral outcomes and inform clinicians on novel interdisciplinary approaches.

5. U01 (PI: Moore; PI, subcontract: Justice/**Lo Re**) 07/01/16 – 06/30/21
Evaluation of End-Stage Liver Disease Events in the NA-ACCORD

This grant will provide funding to evaluate end-stage liver disease events among HIV-infected patients within the Veterans Aging Cohorts Study (VACS) and enable collaboration of the VACS Liver Core with the Liver Working Group of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

6. FDA HHS75F40119D10037 (PI, Subcontract: **Lo Re**) 06/01/20 – 09/30/21
Risk of Arteria and Venous Thrombotic Events with COVID-19 in the FDA's Sentinel System

This project will evaluate health plan members with COVID-19 in the FDA's Sentinel System and will: 1) determine the 90-day incidence of arterial and venous thrombotic complications (evaluated separately), 2) evaluate patient characteristics present prior to COVID-19 diagnosis as risk factors for arterial and venous thrombotic events (evaluated separately), and 3) compare the 90-day risk of arterial and venous thrombotic events (evaluated separately) between health plan members diagnosed with COVID-19 and those diagnosed with influenza.

Completed Research Support

1. F32 DK069080 (PI: **Lo Re**) 08/01/04 – 07/31/06
Weight Loss During Treatment of Hepatitis C in HIV

This epidemiological study examined the incidence of weight loss in HIV/HCV-coinfected patients who receive antiretroviral therapy (ART) and PEG-interferon plus ribavirin compared to: 1) HCV-monoinfected patients who receive treatment with PEG-interferon and ribavirin, and 2) HIV-monoinfected individuals receiving only ART.

2. Bristol Myers-Squibb Virology Fellows Research Award (PI: **Lo Re**) 12/01/04 – 11/30/05

Prevalence and Risk Factors for Occult HBV Infection

This project aimed to: 1) determine the prevalence of occult hepatitis B virus (HBV) infection among HBV surface antigen-negative/HBV core antibody-positive HIV-infected subjects in the Penn CFAR cohort study, and 2) identify risk factors for occult HBV infection in HBV surface antigen-negative/HBV core antibody-positive HIV-infected patients.

3. Penn Center for Education and Research on Therapeutics (PI: **Lo Re**) 09/01/05 – 08/31/06
Outcomes of Occult HBV Infection

This epidemiological study determined if: 2) occult HBV is associated with liver aminotransferase elevations among HBV surface antigen-negative/HBV core antibody-positive HIV-infected patients, and 2) HIV patients with occult HBV have a greater incidence of liver aminotransferase elevations than those without occult HBV.

4. Penn Center for Education and Research on Therapeutics (PI: **Lo Re**) 04/01/06 – 09/30/07
A Pharmacy-Based Time-to-Refill Measure of Adherence to Hepatitis C Virus Therapy

This epidemiological study sought to determine if a pharmacy-based refill-derived measure of adherence to PEG-interferon and ribavirin is associated with decline in HCV RNA at 3-months of HCV therapy.

5. K01 AI070001 (PI: **Lo Re**) 07/15/07 – 04/30/12
Risk Factors and Predictors of Liver Failure in HIV/HCV Patients

This proposal had three Specific Aims: 1) Compare the risk of hepatic decompensation among antiretroviral-treated coinfecting patients compared to HCV-monoinfected patients, 2) Identify risk factors for hepatic decompensation among HIV/HCV-coinfecting patients in the Veterans Aging Cohort Study, and 3) Derive and internally validate a clinical predictive index to stratify coinfecting patients by risk of progression to hepatic decompensation.

6. VISN-4 VA Pilot Project Fund (PI: **Lo Re**) 01/03/09 – 12/31/11
Relationship Between Adherence to Hepatitis C Treatment and Virologic Outcomes

This proposal had three Aims: 1) Determine the level of adherence to PEG-interferon plus ribavirin, as measured by pharmacy refills, which is associated with early and sustained virologic response; 2) Evaluate the changes in adherence to these antivirals over time, and 3) Identify risk factors for non-adherence to PEG-interferon and ribavirin.

7. Penn Center for Education and Research on Therapeutics (PI: **Lo Re**) 01/05/09 – 01/04/10
Outcomes of Heart Transplant Recipients with HCV Infection

This retrospective cohort study evaluated the association between recipient pre-transplant HCV serostatus and survival after heart transplantation among adults who underwent heart transplantation between January 1, 1993 and December 31, 2007 in the U.S. Scientific Registry of Transplant Recipients.

8. Penn Center for AIDS Research Developmental Grant (PI: **Lo Re**) 09/01/09 – 06/30/13
A Structural Approach to Bone Disease Due to Hepatitis C Co-infection in HIV

This study examined trabecular and cortical volumetric bone mineral density and cortical dimensions via

peripheral quantitative CT in HIV/HCV-coinfected women receiving ART compared to: 1) HIV-monoinfected women on ART, 2) HCV-monoinfected women, and 3) uninfected women.

9. R01-HS018372 (PI: **Lo Re**) 09/30/10 – 07/31/16
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications

This proposal seeks to: 1) Determine the population-representative incidence of drug-induced acute liver failure within Kaiser Permanente Northern California (KPNC), 2) Develop a prognostic model to classify patients diagnosed with drug-induced liver injury by their risk of progression to acute liver failure within KPNC; 3) Perform external validation of the prognostic model derived in Aim 2 using data from the University of Pennsylvania; and 4) Determine the risk of acute liver injury associated with antimicrobial medications to provide evidence on the comparative hepatic safety of these drugs.

10. FDA HHSF223200910006I (PI, Subcontract: **Lo Re**) 06/01/11 – 11/30/12
Validation of Severe Acute Liver Injury Diagnoses in Mini-Sentinel

This project determined the ability of ICD-9 diagnosis codes to identify cases of severe acute liver injury within the administrative data sources of the Mini-Sentinel Distributed Database.

11. Gilead Sciences (PI: **Lo Re**) 07/01/11 – 09/30/13
Risk of Hip Fractures Associated with Hepatitis B Virus Infection

This project utilized U.S. Medicaid data to evaluate the risks of hip fracture among patients with untreated and treated HBV infection alone (i.e., HBV-monoinfection) compared to uninfected persons. We then examined the risks of hip fractures among dually-treated HIV/HBV-coinfected patients compared to: 1) treated HBV-monoinfected, 2) HIV-monoinfected on ART, and 3) persons uninfected with either virus.

12. Merck (PI: **Lo Re**) 06/01/13 – 06/30/14
Hepatic Decompensation in HIV/HBV/HCV Patients

This project compared rates of hepatic decompensation in HIV/HBV/HCV and HIV/HCV patients. We then determined the risk of decompensation associated with anti-HBV nucleos(t)ide analogue-untreated and treated HIV/HBV/HCV infection compared to HIV/HCV infection.

13. Penn Patient-Centered Outcomes Research Pilot Program (PI: **Lo Re**) 06/30/15 – 05/31/17
Adherence and Completion of Chronic Hepatitis C Virus Therapy

This pilot grant aims to understand the perceptions of chronic hepatitis C virus (HCV)-infected patients related to barriers and facilitators to completing the HCV continuum of care (i.e., initiation, adherence to antiviral treatment, and retention), by HIV status. We will conduct focus groups among patients with chronic HCV, with and without HIV, and in various stages of HCV treatment and who have achieved HCV cure, to facilitate understanding of patients' expectations and experiences with HCV treatment.

14. AstraZeneca/Bristol-Myers (PI: **Lo Re**) 08/24/10 – 08/23/17
Clinical Outcomes of Saxagliptin

This US Food and Drug Administration and European Medicines Agency-mandated post marketing safety study evaluated the risk of acute liver failure, serious infection, severe hypersensitivity reactions,

acute kidney injury, and major cardiovascular events associated with saxagliptin, a new oral anti-diabetic drug, compared to users of oral anti-diabetic drugs in classes other than DPP-4 inhibitors within two electronic claims-based data sources in the US (Healthcore Integrated Research Database; US Medicare) and two electronic medical record databases in the UK (i.e., Clinical Practice Research Datalink; The Health Improvement Network).

15. R21-AI124868 (PI: **Lo Re**) 02/15/16 – 01/31/18
Risk of Liver Complications with Hepatitis B Viremia During Tenofovir-Based ART

This project seeks to: 1) Determine the risk of serious liver complications (defined as a composite of end-stage liver disease or hepatocellular carcinoma) associated with detectable hepatitis B DNA among HIV/hepatitis B-coinfected patients on tenofovir-based antiretroviral therapy (ART), and 2) Define the risk of serious liver complications associated with HIV viremia in HIV/hepatitis B-coinfected patients on tenofovir-based ART.

16. R21-DK108045 (PI: Reese; Co-Investigator: **Lo Re**) 06/12/17 – 04/30/19
Waiting List and Kidney Transplant Outcomes for Patients with Hepatitis C Infection

This project seeks to: 1) Compare rates of transplantation and death among HCV+ and uninfected dialysis patients on the waiting list for renal transplant, 2) Determine whether renal transplant is associated with a survival benefit compared to chronic dialysis in wait-listed HCV+ patients, and 3) Compare survival associated with transplantation from a HCV+ donor with waiting for a kidney transplant from a HCV- donor.

17. FDA HHSF223201400030I (PI, Subcontract: **Lo Re**) 10/01/17 – 09/30/19
Validation of Serious Infections Among an Immunocompromised Population in Sentinel

This proposal seeks to develop and validate an ICD-10-CM-based diagnostic coding algorithm to identify serious infections among immunocompromised health plan members within the Sentinel Distributed Database.